ACER - Acer Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Acer Therapeutics Inc.

One Gateway Center
Suite 351
Newton, MA 02458
United States
844-902-6100
http://www.acertx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees19

Key Executives

NameTitlePayExercisedYear Born
Mr. Christopher SchellingFounder, Pres, CEO & Director550kN/A1976
Mr. Harry S. PalminCOO & CFO429.25kN/A1970
Dr. William T. Andrews M.D., FACPChief Medical Officer505kN/A1965
Mr. Donald R. JosephChief Legal Officer & Sec.N/AN/A1954
Ms. Jeannie KimVP of Corp. Devel.N/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of various neuroendocrine disorders. The company was founded in 2013 and is headquartered in Newton, Massachusetts.

Corporate Governance

Acer Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.